Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Interest Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Interest Expenses for 10 consecutive years, with $582000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 9.49% to $582000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, down 3.34% year-over-year, with the annual reading at $2.5 million for FY2025, 3.34% down from the prior year.
  • Interest Expenses for Q4 2025 was $582000.0 at Theravance Biopharma, up from $573000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $11.9 million in Q1 2021, with the low at $550000.0 in Q4 2022.
  • Average Interest Expenses over 5 years is $2.1 million, with a median of $643000.0 recorded in 2024.
  • The sharpest move saw Interest Expenses skyrocketed 108.4% in 2021, then tumbled 82.0% in 2022.
  • Over 5 years, Interest Expenses stood at $2.1 million in 2021, then tumbled by 74.26% to $550000.0 in 2022, then rose by 13.27% to $623000.0 in 2023, then grew by 3.21% to $643000.0 in 2024, then decreased by 9.49% to $582000.0 in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $582000.0, $573000.0, and $663000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.